CTLA4 and neoplasm: Immune checkpoint blockers, including antibodies against cytotoxic T lymphocyte antigen-4(CTLA4), programmed cell death protein 1(PD-1) and its ligand PD-L1, enhance T cell anti-tumor immune function (33).